Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT00671112
Title Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Brian Hill, MD, PhD
Indications

diffuse large B-cell lymphoma

follicular lymphoma

anaplastic large cell lymphoma

chronic lymphocytic leukemia

hairy cell leukemia

cutaneous T cell lymphoma

marginal zone B-cell lymphoma

non-Hodgkin lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

Therapies

Bortezomib + Everolimus

Age Groups: adult
Covered Countries USA


No variant requirements are available.